BostonGene Announces Two Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition
Presentations Highlight the Integral Role of Tumor Microenvironment Analysis in Determining Cellular Composition and Gene Expression for Patients with Follicular Lymphoma
Presentations Highlight the Integral Role of Tumor Microenvironment Analysis in Determining Cellular Composition and Gene Expression for Patients with Follicular Lymphoma
WALTHAM, MA, December 1, 2020
BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced that two abstracts were selected for poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. The all-virtual event will be held from December 5 – 8, 2020.
Details of the presentations are below:
Title: Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology
Session: 621: Lymphoma—Genetic/Epigenetic Biology: Poster I
Abstract Number: 1106
Date and Time: Saturday, December 5, 2020: 10:00 AM - 6:30 PM ET
Presenter: Andrea J. Radtke, PhD, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Follicular lymphoma is an indolent B-cell lymphoma with remarkable heterogeneity in disease progression and trajectory; therefore, determining the cell intrinsic and extrinsic factors underlying this clinical heterogeneity is necessary to impact patient clinical outcomes. Using a multi-omics approach, including whole exome sequencing (WES) and bulk RNA-seq integrated with single-cell analyses such as scRNA-seq and multiparameter imaging, notable patient-specific cellular interactions and expression patterns were identified that may drive cancer patient survival. This integrated approach provides insights into both tumor biology and disease trajectory, which can ultimately benefit therapeutic strategies in follicular lymphoma.
Research conducted with the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID), both part of the National Institutes of Health (NIH).
Title: High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles
Session: 622
Abstract Number: 1117
Date and Time: Saturday, December 5, 2020: 10:00 AM - 6:30 PM ET
Presenter: Jose C. Villasboas, MD, Mayo Clinic
Cells of the immune system play an important role in modulating the trajectory of lymphomas; therefore, understanding the composition and spatial distribution of immune cells within the tumor microenvironment (TME) is critical to improve clinical outcomes for patients. Analysis of a follicular lymphoma tumor section that used Co-Detection by Indexing (CODEX) multiplex immunofluorescence image processing identified unique cell subsets and specific spatial distribution of immune cells. These insights into the complex immune cell composition and architecture of the TME add to the prognostic value of the TME as a therapeutic target in follicular lymphoma.
Research conducted with Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Université Claude Bernard Lyon and the University of Iowa.
In addition to the poster presentations, the abstracts have been published online in the November supplemental issue of "Blood”.
For more information, please visit the 62nd ASH Annual Meeting and Exposition website at https://www.hematology.org/meetings/annual-meeting/abstracts.
WALTHAM, MA, December 1, 2020
BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced that two abstracts were selected for poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. The all-virtual event will be held from December 5 – 8, 2020.
Details of the presentations are below:
Title: Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology
Session: 621: Lymphoma—Genetic/Epigenetic Biology: Poster I
Abstract Number: 1106
Date and Time: Saturday, December 5, 2020: 10:00 AM - 6:30 PM ET
Presenter: Andrea J. Radtke, PhD, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Follicular lymphoma is an indolent B-cell lymphoma with remarkable heterogeneity in disease progression and trajectory; therefore, determining the cell intrinsic and extrinsic factors underlying this clinical heterogeneity is necessary to impact patient clinical outcomes. Using a multi-omics approach, including whole exome sequencing (WES) and bulk RNA-seq integrated with single-cell analyses such as scRNA-seq and multiparameter imaging, notable patient-specific cellular interactions and expression patterns were identified that may drive cancer patient survival. This integrated approach provides insights into both tumor biology and disease trajectory, which can ultimately benefit therapeutic strategies in follicular lymphoma.
Research conducted with the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID), both part of the National Institutes of Health (NIH).
Title: High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles
Session: 622
Abstract Number: 1117
Date and Time: Saturday, December 5, 2020: 10:00 AM - 6:30 PM ET
Presenter: Jose C. Villasboas, MD, Mayo Clinic
Cells of the immune system play an important role in modulating the trajectory of lymphomas; therefore, understanding the composition and spatial distribution of immune cells within the tumor microenvironment (TME) is critical to improve clinical outcomes for patients. Analysis of a follicular lymphoma tumor section that used Co-Detection by Indexing (CODEX) multiplex immunofluorescence image processing identified unique cell subsets and specific spatial distribution of immune cells. These insights into the complex immune cell composition and architecture of the TME add to the prognostic value of the TME as a therapeutic target in follicular lymphoma.
Research conducted with Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Université Claude Bernard Lyon and the University of Iowa.
In addition to the poster presentations, the abstracts have been published online in the November supplemental issue of "Blood”.
For more information, please visit the 62nd ASH Annual Meeting and Exposition website at https://www.hematology.org/meetings/annual-meeting/abstracts.
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
